Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Sarcoma 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Gynecological Cancer 1Glioblastoma 1Craniopharyngioma 1Carcinoma, Hepatocellular 1Anlotinib 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 6Irinotecan 6Vincristine 3PM 01183 3Nivolumab 3X-Rays 2Cyclophosphamide 2temsirolimus 1talazoparib 1surufatinib 1silmitasertib 1seclidemstat 1rubitecan 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1irinotecan sucrosofate 1eribulin 1entrectinib 1efineptakin alfa 1dinutuximab 1copanlisib 1bempegaldesleukin 1anlotinib 1alovudine 1abemaciclib 1Zoledronic Acid 1Trabectedin 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Ewing × anlotinib × Clear all
NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown
47 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡